Newsroom | 60940 results

WAYNE, Pa.--(BUSINESS WIRE)--Trinseo PLC (the “Company” or “Trinseo”) (OTCM: TSEOF), a specialty material solutions provider, has today taken the next step to implement the pre-packaged restructuring plan described in the previously announced Restructuring Support Agreement (“RSA”) with parties that hold a significant majority of its debt. The transactions contemplated under the RSA will reduce Trinseo’s debt by approximately $2.0 billion and reduce its annual interest expense by approximately...

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation and Chiba Institute of Technology announced today that they have signed a basic agreement to research and develop homegrown physical AI technologies for public and private sector applications. The two parties will establish a co-creation center and promote the commercialization of AI robotics solutions utilizing a variety of autonomously controlled robots, including multi-legged walking robots, humanoid robots and drone-type robots. The ag...

SYDNEY--(BUSINESS WIRE)--Avetta®, the leader in intelligent work readiness across global supply chains, today announced the results of its work with construction and infrastructure services company Odina Industries. Avetta supported Odina to drive down its contractor approval times by 50% whilst also dropping its administrative workload by 30%. The collaboration has ensured faster onboarding of suppliers and a renewed focus on high-value tasks and strategic growth for the company. Odina provide...

BENGALURU, India--(BUSINESS WIRE)--TVS Motor Company has been ranked #1 globally in the ‘Durable Consumer Goods’ category in the annual ‘Best Stocks in the World’, ranking....

MELBOURNE, Australia--(BUSINESS WIRE)--MotorOne, the Australian automotive aftermarket group, partnered with FINEDIGITAL to broaden its offering into software-enabled vehicle solutions....

ZOUG, Suisse--(BUSINESS WIRE)--Polpharma Biologics, une société biopharmaceutique de premier plan spécialisée dans le développement et la fabrication de médicaments biosimilaires, a annoncé aujourd’hui la signature d’un accord de licence historique avec la société argentine Tuteur. Dans le cadre de ce partenariat stratégique, Tuteur obtiendra les droits exclusifs de commercialisation d’un médicament biosimilaire destiné au traitement des maladies auto-immunes dans toute l’Amérique latine (LATAM...

ZUG, Schweiz--(BUSINESS WIRE)--Polpharma Biologics, ein führendes biopharmazeutisches Unternehmen für die Entwicklung und Herstellung von Biosimilaren, hat heute die Unterzeichnung eines wichtigen Lizenzvertrags mit dem in Argentinien ansässigen Unternehmen Tuteur bekannt gegeben. Im Rahmen dieser strategischen Partnerschaft erhält Tuteur das exklusive Recht, ein Biosimilar gegen Autoimmunkrankheiten in Lateinamerika (LATAM) mit Ausnahme von Brasilien zu vertreiben. Polpharma Biologics wird die...

HYDERABAD, India & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced plans to open a new manufacturing facility in Hyderabad, India in 2027, create more than 300 direct jobs, and spend approximately $200 million in both ca...

瑞士楚格--(BUSINESS WIRE)--(美國商業資訊)-- 專注于生物相似藥開發與生產的一流生物製藥公司Polpharma Biologics今日宣布，已與總部位於阿根廷的Tuteur簽署一項具有里程碑意義的授權協議。根據這一策略性合作夥伴關係，Tuteur將獲得一款用於治療自身免疫性疾病的生物相似藥在拉丁美洲（不包括巴西）地區的獨家商業化權益。 Polpharma Biologics將全權負責該生物相似藥的開發和生產工作。Tuteur則將負責其在獲准授權區域內的商業化、行銷及經銷。此次合作體現了雙方的共同承諾，即致力於提高高品質、可負擔的生物療法對整個拉丁美洲地區病患的可及性。 Polpharma Biologics執行長Anjan Selz表示：「與Tuteur合作是推進我們在全球擴大生物相似藥可及性這一使命的重要一步。憑藉其在拉丁美洲深厚的本土專業知識和商業化能力，我們完全有能力將這一重要療法帶給飽受自身免疫性疾病困擾的病患。我們的共同目標是提高有效且可負擔的治療選擇對整個地區的可及性。」 Tuteur總裁Jonathan Hahn表示：「我們與Polpharma Bio...

瑞士楚格--(BUSINESS WIRE)--(美国商业资讯)-- 专注于生物类似药开发与生产的领先生物制药公司Polpharma Biologics今日宣布，已与总部位于阿根廷的Tuteur签署一项具有里程碑意义的授权协议。根据这一战略合作伙伴关系，Tuteur将获得一款用于治疗自身免疫性疾病的生物类似药在拉丁美洲（不包括巴西）地区的独家商业化权益。 Polpharma Biologics将全权负责该生物类似药的开发和生产工作。Tuteur则将负责其在获批许可区域内的商业化、营销及分销。此次合作体现了双方的共同承诺，即致力于提高高质量、可负担的生物疗法对整个拉丁美洲地区患者的可及性。 Polpharma Biologics首席执行官Anjan Selz表示：“与Tuteur合作是推进我们在全球范围内扩大生物类似药可及性这一使命的重要一步。凭借其在拉丁美洲深厚的本土专业知识和商业化能力，我们完全有能力将这一重要疗法带给饱受自身免疫性疾病困扰的患者。我们的共同目标是提高有效且可负担的治疗选择对整个地区的可及性。” Tuteur总裁Jonathan Hahn表示：“我们与Polpharma...